Status:
UNKNOWN
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
Lead Sponsor:
Kantonsspital Graubuenden
Conditions:
Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific
Eligibility:
All Genders
Brief Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and VEGF on platelet clustering. PURPOSE: This research st...
Detailed Description
OBJECTIVES: * To determine the influence of bevacizumab on platelet aggregation in patients receiving bevacizumab for cancer. * To determine the influence of VEGF on platelet aggregation. * To determ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Receiving bevacizumab for cancer
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
October 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00898794
Start Date
October 1 2007
Last Update
August 7 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kantonsspital Graubuenden
Chur, Switzerland, CH-7000